Mitomycine Medac (Mitomycin)

Mitomycin is a bioreductive alkylating agent. Inside cancer cells, it is reduced to a reactive intermediate that forms covalent cross‑links between DNA strands. This cross‑linking blocks DNA replication and transcription, leading to apoptosis of rapidly dividing bladder tumor cells.

The exact dose and schedule of Mitomycine Medac are determined by the prescribing oncologist or urologist based on the patient’s clinical condition, tumor stage, and prior treatments. The healthcare professional tailors the regimen to achieve optimal therapeutic effect while minimizing toxicity.

Mitomycine Medac is classified as contraindicated in pregnancy and breastfeeding because mitomycin can cause fetal toxicity and is excreted in breast milk. Women of childbearing potential should use effective contraception and discuss any pregnancy plans with their physician before treatment.

To order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s commercial team will verify eligibility, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mitomycine Medac (mitomycin) is a DNA‑cross‑linking antibiotic, whereas alternatives like Bacillus Calmette‑Guerin (BCG) are immunotherapies. Mitomycin provides direct cytotoxicity with a shorter treatment course, while BCG stimulates an immune response. Choice depends on tumor characteristics, prior therapy, and patient tolerance.

Store Mitomycine Medac at or below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Before use, inspect the vial for any particulate matter or discoloration and handle with aseptic technique to maintain sterility.

The drug is administered intravesically: a sterile solution is instilled into the bladder through a catheter, typically retained for a specified dwell time (often 1–2 hours) before the patient voids. The procedure is performed in a clinical setting under the supervision of a qualified healthcare professional.

Serious risks include severe hemorrhagic cystitis, bladder fibrosis, systemic bone‑marrow suppression leading to leukopenia or anemia, and rare allergic reactions. Patients should be monitored for signs of bleeding, infection, or blood count abnormalities, and treatment should be discontinued if severe toxicity occurs.

Patients with active urinary tract infection, gross hematuria, severe renal impairment, known hypersensitivity to mitomycin, or those who are pregnant or breastfeeding should not receive Mitomycine Medac. Additionally, individuals receiving concurrent therapies that markedly increase bladder toxicity should be evaluated carefully.